Experts unpack relapsed myeloma sequencing—risk factors, referrals, and earlier CAR‑T and bispecific therapies to personalize care and support patients.
Back
How I Treat Relapsed/Refractory Multiple Myeloma: Navigating Treatment Selection, Sequencing, and Personalized Care in an Evolving Therapeutic Landscape
In this OncLive® Insights program, Dr. Joshua Richter and Dr. Marco Davila provide an evidence-based discussion on the evolving management of relapsed/refractory multiple myeloma (RRMM), with a focus on optimizing treatment selection, sequencing, and personalized patient care. The conversation explores how recent clinical evidence is influencing earlier integration of advanced therapies, while emphasizing patient identification, disease risk assessment, and individualized treatment planning. Dr. Richter and Dr. Davila discuss practical considerations that extend beyond efficacy data, including appropriate timing of referral to specialized centers, multidisciplinary collaboration, bridging therapy, and coordination between community and academic practices. Through case-based discussions, they examine real-world approaches to managing patients with standard-risk and high-risk disease, highlighting factors that influence therapeutic decision-making across different clinical scenarios. The program also addresses patient quality of life, caregiver engagement, and remaining challenges in improving access to innovative therapies, providing clinicians with practical, balanced insights for delivering personalized care to patients with relapsed/refractory multiple myeloma.
How I Treat Relapsed/Refractory Multiple Myeloma: Navigating Treatment Selection, Sequencing, and Personalized Care in an Evolving Therapeutic Landscape
Episodes
All
All
Experts unpack relapsed myeloma sequencing—risk, refractoriness, and support—plus earlier CAR T and bispecifics shaping personalized care.
Dr. Joshua Richter and Dr. Marco Davila examine how real-world evidence is shaping the use of CAR T-cell therapy for relapsed/refractory multiple myeloma (RRMM) beyond the results of pivotal clinical trials.
Dr. Joshua Richter and Dr. Marco Davila discuss how clinicians determine the optimal timing for CAR T-cell therapy in relapsed/refractory multiple myeloma (RRMM), emphasizing that treatment decisions should be individualized rather than based solely on line of therapy.
Dr. Joshua Richter and Dr. Marco Davila discuss the ideal timing for referral to a cellular therapy specialist for patients with relapsed/refractory multiple myeloma (RRMM).
Dr. Joshua Richter and Dr. Marco Davila discuss practical strategies for bridging therapy in relapsed/refractory multiple myeloma (RRMM) as patients transition to CAR T-cell therapy.
Dr. Joshua Richter and Dr. Marco Davila discuss how to counsel patients with relapsed/refractory multiple myeloma (RRMM) about recovery and long-term follow-up after CAR T-cell therapy.
Dr. Joshua Richter and Dr. Marco Davila discuss the essential role of multidisciplinary care and caregiver engagement in the management of relapsed/refractory multiple myeloma (RRMM), particularly for patients undergoing CAR T-cell therapy.
Dr. Joshua Richter and Dr. Marco Davila present a case of a patient with relapsed/refractory multiple myeloma (RRMM) experiencing first relapse after initial therapy and discuss whether patients considered ineligible for autologous stem cell transplantation may still be candidates for CAR T-cell therapy.
Dr. Joshua Richter and Dr. Marco Davila discuss the rationale for incorporating CAR T-cell therapy earlier in the treatment course for relapsed/refractory multiple myeloma (RRMM).
Dr. Joshua Richter and Dr. Marco Davila discuss the importance of aligning treatment decisions with individual patient goals in relapsed/refractory multiple myeloma (RRMM), particularly among older adults being considered for CAR T-cell therapy.
Dr. Joshua Richter and Dr. Marco Davila discuss how to prepare patients with relapsed/refractory multiple myeloma (RRMM) for the CAR T-cell therapy process by setting clear expectations before treatment begins.
Dr. Joshua Richter and Dr. Marco Davila discuss the importance of collaboration between specialized cellular therapy centers and community oncologists to improve access to CAR T-cell therapy for patients with relapsed/refractory multiple myeloma (RRMM).
Dr. Joshua Richter and Dr. Marco Davila discuss a case of a patient with relapsed/refractory multiple myeloma (RRMM) who has high-risk, rapidly progressive disease but faces practical barriers to receiving CAR T-cell therapy, including travel distance, caregiver availability, and time away from home.
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Imlunestrant Plus Abemaciclib for ER+, HER2–, ESR1-Mutated Metastatic Breast Cancer
2
Five Under 5: Top Oncology Videos for the Week of 9/13
3
Updated NCCN Guidelines Feature Additional MRD Recommendations in Multiple Myeloma
4
The OncFive: Top Oncology Articles for the Week of 9/14/2026
5